# OnCo record nct06760637 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06760637/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06760637", "NCT06760637" ;
  schema:name "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease"@en ;
  schema:alternateName "FOURLIGHT-3"@en ;
  schema:description "A phase 3 trial of Atirmociclib, Abemaciclib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Pfizer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06760637/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06760637> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-01-06" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/atirmociclib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/ribociclib/> ;
  onco:companies <https://onco.cc/companies/pfizer/> .